Septarna [SEPN] vs Capricor [CAPR] Detailed Stock Comparison

Septarna Inc.

NASDAQ
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Septarna Inc. wins in 9 metrics, Capricor Therapeutics Inc. wins in 5 metrics, with 0 ties. Septarna Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Septarna Inc. Capricor Therapeutics Inc. Better
P/E Ratio (TTM) N/A -15.61 N/A
Price-to-Book Ratio 2.89 6.62 Septarna Inc.
Debt-to-Equity Ratio 6.19 4.75 Capricor Therapeutics Inc.
PEG Ratio -12.68 -0.05 Capricor Therapeutics Inc.
EV/EBITDA -9.35 -16.23 Septarna Inc.
Profit Margin (TTM) -106.37% 0.00% Capricor Therapeutics Inc.
Operating Margin (TTM) -66.44% 0.00% Capricor Therapeutics Inc.
Return on Equity -12.19% -46.56% Septarna Inc.
Return on Assets (TTM) -9.59% -25.68% Septarna Inc.
Free Cash Flow (TTM) $109.67M $-81.54M Septarna Inc.
1-Year Return 226.49% 202.93% Septarna Inc.
Price-to-Sales Ratio (TTM) 24.11 N/A N/A
Enterprise Value $740.38M $1.72B Capricor Therapeutics Inc.
EV/Revenue Ratio 16.11 N/A N/A
Revenue per Share (TTM) $1 $0 Septarna Inc.
Earnings per Share (Diluted) $-1.10 $-2.26 Septarna Inc.
Beta (Stock Volatility) N/A 0.48 N/A
Short % of Float 9.41% 19.17% Septarna Inc.

Septarna Inc. vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

SEPN
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Septarna Inc.2.04%2.55%23.09%8.60%15.07%9.19%
Capricor Therapeutics Inc.1.10%-5.15%-17.49%6.97%-7.74%-2.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Septarna Inc.226.49%41.12%41.12%41.12%41.12%41.12%
Capricor Therapeutics Inc.202.93%558.46%676.17%-7.24%-90.64%-97.72%

Performance & Financial Health Analysis: Septarna Inc. vs Capricor Therapeutics Inc.

MetricSEPNCAPR
Market Information
Market Cap i$1.11B$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i420,760987,380
90 Day Avg. Volume i311,7771,234,213
Last Close$30.55$27.64
52 Week Range$9.70 - $32.63$4.30 - $40.37
% from 52W High-6.37%-31.53%
All-Time High$32.63 (Feb 25, 2026)$3,500.00 (Oct 22, 2007)
% from All-Time High-6.37%-99.21%
Growth Metrics
Quarterly Revenue Growth112.76%N/A
Quarterly Earnings Growth112.76%-1.00%
Financial Health
Profit Margin (TTM) i-1.06%0.00%
Operating Margin (TTM) i-0.66%0.00%
Return on Equity (TTM) i-0.12%-0.47%
Debt to Equity (MRQ) i6.194.75
Cash & Liquidity
Book Value per Share (MRQ)$8.52$5.33
Cash per Share (MRQ)$8.71$5.53
Operating Cash Flow (TTM) i$110.19M$-69,811,264
Levered Free Cash Flow (TTM) i$18.81M$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Septarna Inc. vs Capricor Therapeutics Inc.

MetricSEPN (Apr 26, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A-15.61
Forward P/E i-12.68-56.73
PEG Ratio i-12.68-0.05
Price to Sales (TTM) i24.11N/A
Price to Book (MRQ) i2.896.62
Market Capitalization
Market Capitalization i$1.11B$2.04B
Enterprise Value i$740.38M$1.72B
Enterprise Value Metrics
Enterprise to Revenue i16.11N/A
Enterprise to EBITDA i-9.35-16.23
Risk & Other Metrics
Beta iN/A0.48
Book Value per Share (MRQ) i$8.52$5.33

Financial Statements Comparison: Septarna Inc. vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSEPN (2025)CAPR (2025)
Revenue/Sales i45.95M0
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i97.58M84.45M
Operating Income (EBIT) i-80.80M-108.14M
Operating Margin i-175.8%-
EBITDA i-91.69M-106.21M
EBITDA Margin i-199.5%-
Pre-Tax Income i-48.87M-105.04M
Pre-Tax Income % of Revenue i-106.3%-
Income Tax i12,0001,600
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-48.88M-105.04M
Profit Margin i-106.4%-

Balance Sheet & Liquidity Metrics

MetricSEPN (2025)CAPR (2025)
Cash & Equivalents i120.72M287.85M
Total Current Assets i410.96M322.94M
Total Current Assets % of Revenue i894.4%-
Total Current Liabilities i86.93M35.84M
Total Current Liabilities % of Revenue i189.2%-
Long-Term Debt i21.41M14.32M
Long-Term Debt % of Revenue i46.6%-
Total Shareholders Equity i381.93M305.79M
Retained Earnings i-167.25M-304.88M
Retained Earnings % of Revenue i-364.0%-
Property, Plant & Equipment i27.84M22.27M

Cash Flow Statement Comparison

MetricSEPN (2025)CAPR (2025)
Operating Cash Flow i125.56M-71.86M
Operating Cash Flow % of Revenue i273.2%-
Capital Expenditures i-518,000-11.72M
Free Cash Flow i109.67M-81.54M
FCF Margin i238.7%-
Debt Repayment iN/AN/A
Common Stock Repurchase i-1,000N/A

Short Interest & Institutional Ownership Analysis

MetricSEPNCAPR
Shares Short i2.46M10.04M
Short Ratio i8.857.73
Short % of Float i9.41%19.17%
Shares Outstanding i44.81M57.37M
Float Shares i22.90M48.61M
% Held by Insiders i3.14%9.47%
% Held by Institutions i102.97%53.91%
% Held by Public i-6.11%36.62%

Dividend Analysis & Yield Comparison: Septarna Inc. vs Capricor Therapeutics Inc.

MetricSEPNCAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A